Albuminuria may mark renal risk without defining a treatment threshold

Agreement: I Agree Body: Dear Editor, Turchin and colleagues report an important target trial emulation in which glucagon-like peptide-1 receptor agonists (GLP-1RAs) or sodium-glucose cotransporter-2 (SGLT2) inhibitors were associated with a lower five-year risk of renal deterioration than dipeptidyl peptidase-4 inhibitors among people with albuminuria (3.2% v 5.4%; risk ratio 0.60), but not among those without albuminuria (2.4% v 2.1%; risk ratio 1.10).[1] The latter finding is informative for